Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure (GENETIC-AF)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by ARCA Biopharma, Inc.
Information provided by (Responsible Party):
ARCA Biopharma, Inc. Identifier:
First received: October 23, 2013
Last updated: October 13, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)